SB-742457 is a selective 5-HT6 receptor antagonist with cognition memory and learning-enhancing effects. It is currently under development by GlaxoSmithKline for the treatment of Alzheimer’s disease and has demonstrated preliminary efficacy in phase II clinical trials.
This page contains content from the copyrighted Wikipedia article "SB-742457"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
